dilut
nasal
aspir
sampl
taken
children
southampton
area
acut
natur
occur
cold
associ
exacerb
asthma
part
anoth
studi
children
age
year
present
studi
obtain
nasal
aspir
sampl
period
acut
asthma
exacerb
children
boy
girl
atop
nonatop
obtain
anoth
sampl
children
asymptomat
acut
exacerb
sampl
select
child
proven
viral
infect
suffici
nasal
aspir
remain
acut
asymptomat
sampl
complet
previou
studi
plan
assay
method
sampl
collect
describ
rhinovirus
detect
polymeras
chain
reaction
pcr
previous
report
detect
respiratori
virus
cell
cultur
five
cell
line
immunofluoresc
microscopi
serolog
differenti
rhinovirus
enterovirus
done
acid
labil
test
full
detail
method
publish
measur
rant
nasal
aspir
elisa
accord
manufactur
protocol
r
system
abingdon
uk
lower
limit
detect
rant
nasal
aspir
pgml
respect
gmcsf
elisa
use
pair
antibodi
specif
gmcsf
pharmingen
cambridg
uk
elisa
perform
accord
manufactur
protocol
lower
limit
detect
pgml
eosinophil
mbp
nasal
aspir
measur
duplic
use
twosit
ria
previous
describ
lower
limit
detect
mbp
ngml
use
mannwhitney
u
test
examin
differ
cytokin
level
nasal
aspir
sampl
obtain
symptomat
asymptomat
examin
rant
level
atop
nonatop
children
symptomat
sampl
spearman
rank
correl
use
examin
relationship
mbp
rant
level
respiratori
symptom
score
acut
asthma
exacerb
cytokin
mbp
level
report
analyz
measur
dilut
nasal
aspir
sampl
children
acut
asthma
exacerb
rhinovirus
detect
influenza
viru
type
parainfluenza
viru
type
adenoviru
coronaviru
rhinoviru
also
detect
asymptomat
sampl
although
weak
pcr
signal
signific
episod
upper
respiratori
symptom
report
exacerb
lower
respiratori
episod
character
cough
wheez
short
breath
least
moder
sever
record
signific
drop
peak
flow
pef
episod
defin
previous
report
median
maxim
percentag
fall
pef
baselin
episod
equival
fall
lmin
figur
show
symptom
pef
virus
identifi
studi
children
illustr
natur
clinic
episod
analyz
studi
level
rant
sampl
obtain
period
acut
exacerb
significantli
higher
median
pgml
rang
pgml
rang
respect
sampl
obtain
children
asymptomat
median
pgml
rang
pgml
rang
respect
p
figur
sampl
atop
nonatop
children
compar
concentr
rant
higher
nasal
aspir
atop
children
nonatop
children
acut
exacerb
asthma
median
rant
level
vs
pgml
respect
median
vs
pgml
respect
howev
differ
reach
statist
signific
concentr
gmcsf
n
mbp
n
n
measur
nasal
aspir
suffici
materi
remain
gmcsf
concentr
mostli
undetect
sampl
symptomat
asymptomat
children
median
valu
limit
detect
pgml
gmcsf
elisa
level
tend
increas
nasal
aspir
symptomat
compar
asymptomat
children
median
pgml
rang
vs
pgml
rang
howev
differ
fail
reach
statist
differ
p
mbp
level
significantli
higher
sampl
acut
exacerb
episod
median
ngml
rang
asymptomat
period
median
ngml
rang
p
figur
signific
correl
mbp
rant
level
r
p
n
mbp
level
r
p
n
nasal
sampl
period
acut
exacerb
investig
possibl
relationship
eosinophil
influx
activ
local
respiratori
symptom
sought
correl
level
mbp
sever
previous
defin
upper
respiratori
tract
symptom
record
episod
signific
correl
sever
upper
respiratori
symptom
mbp
level
r
p
n
similarli
signific
correl
found
sever
also
previous
defin
lower
respiratori
symptom
mbp
concentr
r
p
n
studi
observ
increas
level
eosinophil
chemoattract
rant
eosinophil
product
mbp
nasal
aspir
children
period
proven
virusinduc
asthma
exacerb
data
implic
chemokin
eosinophil
recruit
activ
virusinduc
asthma
suggest
receptor
may
repres
promis
target
develop
therapi
virusinduc
asthma
respiratori
syncyti
viru
induc
select
product
rant
upper
airway
epitheli
cell
vitro
present
studi
show
viral
infect
upper
respiratori
tract
induc
releas
chemokin
rant
releas
eosinophil
product
mbp
vivo
interest
chemokin
eosinophil
chemoattract
less
potent
rant
eosinophil
chemoattract
import
mediat
inflammatori
respons
viral
infect
furthermor
mous
model
absenc
bind
strongli
result
reduc
host
defens
infect
tilt
favor
respons
infect
given
role
cell
asthma
properti
suggest
rant
may
import
mediat
virusinduc
asthma
exacerb
observ
support
find
level
cytokin
atop
children
greater
nonatop
children
observ
increas
chemokin
mediat
level
upper
airway
children
simultan
virusrel
cold
asthma
exacerb
known
properti
chemokin
strongli
suggest
like
import
eosinophil
recruit
activ
upper
airway
therefor
implic
like
import
eosinophil
recruit
activ
known
import
pathogenesi
virusinduc
asthma
exacerb
data
suggest
studi
investig
import
chemokin
lower
airway
done
test
hypothesi
lack
correl
chemokin
level
either
eosinophil
mediat
level
respiratori
symptom
rais
doubt
relev
chemokin
eosinophil
recruit
activ
airway
howev
correl
difficult
find
clinic
studi
mani
variabl
may
affect
strength
relationship
two
biolog
measur
exampl
chemokin
eotaxin
may
also
involv
perhap
concert
rant
furthermor
find
correl
still
proof
causal
relationship
two
variabl
view
known
biolog
function
chemokin
presenc
increas
eosinophil
mediat
suffici
support
hypothesi
chemokin
import
eosinophil
recruit
activ
vivo
studi
chemokin
antagonist
requir
test
strength
relationship
cytokin
eosinophil
product
mbp
detect
nasal
aspir
could
deriv
local
product
serum
via
vascular
leakag
believ
high
level
detect
especi
consid
mucu
dilut
time
storag
analysi
suggest
local
product
predomin
gmcsf
two
cytokin
play
import
role
leukocyt
traffick
gmcsf
chemotact
neutrophil
eosinophil
import
eosinophil
hematopoiesi
prime
chemoattract
concentr
gmcsf
nasal
secret
mostli
undetect
suggest
cytokin
play
minor
role
pathogenesi
natur
occur
virusinduc
asthma
exacerb
find
consist
previou
report
show
gmcsf
play
minor
role
upper
respiratori
viral
infect
small
group
children
enough
clinic
materi
remain
also
investig
presenc
although
level
tend
increas
nasal
aspir
symptomat
children
signific
differ
symptomat
asymptomat
children
role
viral
exacerb
asthma
must
studi
greater
number
children
summari
found
increas
level
chemokin
rant
nasal
secret
exacerb
asthma
associ
upper
respiratori
viral
infect
children
compar
asymptomat
sampl
children
gmcsf
detect
nasal
aspir
concentr
tend
increas
sampl
symptomat
children
studi
also
found
increas
level
eosinophil
granul
protein
mbp
virusinduc
exacerb
asthma
find
suggest
develop
new
drug
neutral
effect
rant
eosinophil
may
affect
virusinduc
asthma
exacerb
